Comparative Efficacy and Safety of Immunotherapy on Non–Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Network Meta‐Analysis
The Clinical Respiratory Journal · 2024
DOI: 10.1111/crj.13823 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Clinical Respiratory Journal, 2024. Verfasst von Tianyi Lyu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Acupuncture Department, Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, Chi…. Hauptthemen laut MEDLINE: Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National High Level Hospital Clinical Research Funding, Elite Medical Professionals Project of China-Japan Friendship Hospital, Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Growing evidence suggests that immunotherapy has a positive effect on non–small cell lung cancer (NSCLC) patients with brain metastases (BMs). However, it remains unclear which type of immunotherapy is more efficient. The aim of this network meta‐analysis (NMA) was to compare the efficacy and safety of different immunotherapy types and determine the optimal option.
Method
Four databases (PubMed, Cochrane Library databases, Embase, and Web of Science) and ClinicalTrial.gov were searched from inception until January 26, 2023. Randomized controlled trials (RCTs), prospective nonrandomized trials, or observational studies investigating NSCLC patients with BMs treated by immunotherapy were included. The quality of the included studies was evaluated using the Cochrane risk of bias (ROB) tool and the Newcastle‐Ottawa Scale (NOS). The efficacy of immunotherapy on NSCLC patients with BMs was evaluated using frequentist random‐effects NMA.
Result
Eleven studies from 1560 citations, encompassing 1437 participants, were included in this NMA. Statistical analysis showed that pembrolizumab (SMD = 4.35, 95% CI [2.21, 6.60]) and nivolumab+ipilimumab (SMD = 3.81, 95% CI [1.21, 6.40]) could improve overall survival (OS). Pembrolizumab (SMD = 3.32, 95% CI [2.75, 3.90]) demonstrated better effects in improving the overall response rate (ORR). No significant difference in adverse event (AE) was observed between immunotherapy and chemotherapy.
Conclusion
Our findings indicated that pembrolizumab was the most promising immunotherapy for NSCLC patients with BMs. Nivolumab+ipilimumab might be an alternative choice to improve OS. Limitation Inconsistency tests were not performed because of the scarcity of direct comparison. Besides, high heterogeneity was observed in our NMA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Acupuncture Department, Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, China.
- Asset Management Division, Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing, China.
- National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Department of Traditional Chinese Medicine fo…
- School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.
- Surgical Department, Dongfang Hospital Beijing University of Chinese Medicine, Beijing, China.
ORCID-Profile: Tianyi Lyu
Förderung
- National High Level Hospital Clinical Research Funding
- Elite Medical Professionals Project of China-Japan Friendship Hospital
- Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine
Zitieren
APA
Lyu, T., Sun, B., Yang, D., Zhao, X., Wang, R., Shu, X., Li, D., & Chen, H. (2024). Comparative Efficacy and Safety of Immunotherapy on Non–Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Network Meta‐Analysis. The Clinical Respiratory Journal. https://doi.org/10.1111/crj.13823
Vancouver
Lyu T, Sun B, Yang D, Zhao X, Wang R, Shu X, et al. Comparative Efficacy and Safety of Immunotherapy on Non–Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Network Meta‐Analysis. The Clinical Respiratory Journal. 2024. doi:10.1111/crj.13823
BibTeX
@article{Lyu2024,
author = {Lyu, Tianyi and Sun, Bo and Yang, Daowen and Zhao, Xirui and Wang, Ruoshui and Shu, Xinyang and Li, Demin and Chen, Hong},
title = {Comparative Efficacy and Safety of Immunotherapy on Non–Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Network Meta‐Analysis},
journal = {The Clinical Respiratory Journal},
year = {2024},
doi = {10.1111/crj.13823}
}
EUVIMED